Cargando…

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

BACKGROUND: Current evidence suggests that patients with Luminal A early breast cancer can skip chemotherapy or extended endocrine therapy, but immunohistochemistry-based biomarker analysis for St Gallen subtyping may not be reproducible. We asked whether RT-qPCR can be used instead to address this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laible, Mark, Hartmann, Kerstin, Gürtler, Claudia, Anzeneder, Tobias, Wirtz, Ralph, Weber, Stephan, Keller, Thomas, Sahin, Ugur, Rees, Martin, Ramaswamy, Annette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631550/ https://www.ncbi.nlm.nih.gov/pubmed/31307414 http://dx.doi.org/10.1186/s12885-019-5890-z

Ejemplares similares

Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma
por: Mishra, Anjali, et al.
Publicado: (2020)

PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer
por: Rees, Michael, et al.
Publicado: (2020)

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells
por: Thaler, Sonja, et al.
Publicado: (2017)

Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2015)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
por: Batra, Atul, et al.
Publicado: (2020)

Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment
por: Akinnusi, Precious A, et al.
Publicado: (2022)

An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019)

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
por: Collins, Denis, et al.
Publicado: (2017)

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer
por: Wang, Caifeng, et al.
Publicado: (2020)

Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor
por: Waqar, Samina, et al.
Publicado: (2018)

ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance
por: Strillacci, Antonio, et al.
Publicado: (2022)

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer
por: Hagio, Kanako, et al.
Publicado: (2021)

Reply to Letter to Editor: “HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?”
por: Li, Shuai, et al.
Publicado: (2020)

Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
por: de Souza, Ana Amélia, et al.
Publicado: (2019)

Differential Activation of a Mouse Estrogen Receptor β Isoform (mERβ2) with Endocrine-Disrupting Chemicals (EDCs)
por: Donoghue, Lauren J., et al.
Publicado: (2016)

Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER)
por: Ma, Shao, et al.
Publicado: (2015)

Functions and physiological roles of two types of estrogen receptors, ERα and ERβ, identified by estrogen receptor knockout mouse
por: Lee, Hye-Rim, et al.
Publicado: (2012)

A role for estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) in collagen biosynthesis in mouse skin
por: Markiewicz, Margaret, et al.
Publicado: (2012)

The Effects of Mono-(2-Ethylhexyl) Phthalate (MEHP) on Human Estrogen Receptor (hER) and Androgen Receptor (hAR) by YES/YAS In Vitro Assay
por: Kim, Da-Hye, et al.
Publicado: (2019)

Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer
por: Pizon, Monika, et al.
Publicado: (2018)

Estrogen receptor degradation: a CUE for endocrine resistance?
por: Musgrove, Elizabeth A
Publicado: (2011)

Estrogen Receptors as Molecular Targets of Endocrine Therapy for Glioblastoma
por: González-Mora, Andrea Magali, et al.
Publicado: (2021)

Biomarker Genes for Detecting Estrogenic Activity of Endocrine Disruptors via Estrogen Receptors
por: Jung, Eui-Man, et al.
Publicado: (2012)

Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor
por: Mal, Rahul, et al.
Publicado: (2020)

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2023)

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2023)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET
por: Antunes, I. F., et al.
Publicado: (2020)

The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer
por: Rodriguez, David, et al.
Publicado: (2019)

HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation
por: Park, B-W, et al.
Publicado: (2005)

Toxicological Mechanism of Endocrine Disrupting Chemicals:Is Estrogen Receptor Involved?
por: Jeung, Eui-Bae, et al.
Publicado: (2010)

Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability
por: Jeffreys, Sarah A., et al.
Publicado: (2020)

Role of estrogen receptor coregulators in endocrine resistant breast cancer
por: Altwegg, Kristin A., et al.
Publicado: (2021)

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
por: Bidard, Francois-Clement, et al.
Publicado: (2022)

Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer
por: Mao, XiaoDan, et al.
Publicado: (2019)

The Co-Expression of Estrogen Receptors ERα, ERβ, and GPER in Endometrial Cancer
por: Hojnik, Marko, et al.
Publicado: (2023)

Pancreatic Insulin Content Regulation by the Estrogen Receptor ERα
por: Alonso-Magdalena, Paloma, et al.
Publicado: (2008)

Classical Estrogen Receptors and ERα Splice Variants in the Mouse
por: Irsik, Debra L., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h9oqjsr9us5e4qddjuld5bnjnp